Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night

Schiza, Sophia; Mermigkis, Charalampos; Margaritopoulos, George; Daniil, Zoi; Harari, Sergio; Poletti, Venerino; Renzoni, Elisabetta A.; Torre, Olga; Visca, Dina; Bouloukaki, I; Sourvinos, George; Αντωνίου, Κατερίνα

doi:10.1183/16000617.00009114

Cited by 58 publications

(33 citation statements)

References 125 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, several studies have focused on the relationship between sleep apnoea and IPF, frequently reporting moderate-to-severe obstructive sleep apnoea (OSA) in IPF patients (defined by an apnoeahypopnoea index >15 events•h −1 ) [97][98][99][100][101][102][103]. The relationship between IPF and OSA is very complex.…”

Section: Sleep Apnoeamentioning

confidence: 99%

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue

et al. 2019

Self Cite

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death may be due to comorbidities occurring in this ageing population. Interest in the role played by comorbidities in IPF has increased in the past few years. The optimal clinical management of IPF is multifaceted and not only involves antifibrotic treatment, but also vaccinations, oxygen supplementation, evaluation of nutritional status as well as psychological support and patient education. Symptom management, pulmonary rehabilitation, palliative care and treatment of comorbidities represent further areas of clinical intervention. This review analyses the major comorbidities observed in IPF, focusing on those that have the greatest impact on mortality and quality of life (QoL). The identification and treatment of comorbidities may help to improve patients' health-related QoL (i.e. sleep apnoea and depression), while some comorbidities (i.e. lung cancer, cardiovascular diseases and pulmonary hypertension) influence survival. It has been outlined that gathering comorbidities data improves the prediction of survival beyond the clinical and physiological parameters of IPF.

show abstract

Section: Sleep Apnoeamentioning

confidence: 99%

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall, published research has reported a distortion of sleep architecture, including decreased sleep efficiency, increased sleep fragmentation, and sleep-related hypoventilation in patients with IPF, while OSA was also frequently observed [7,8]. The reported prevalence of OSA in the literature is 6-91%, and several reports have suggested its close association with quality of life and prognosis in patients with IPF [9]. After the IPF diagnostic criteria were more clearly defined in 2002 by the American Thoracic Society/European Respiratory Society, studies on sleep disorders in IPF patients began to be conducted in earnest.…”

Section: Epidemiologic Evidence Of the Association Between Osa And Ipfmentioning

confidence: 99%

“…In addition, as in OSA, IPF and COPD patients show sympathetic overactivity and endothelial dysfunction. Cardiovascular disease and pulmonary hypertension are frequently observed in IPF and COPD patients, as in OSA [9,37]. However, it remains unclear whether IH or chronic hypoxia promotes more severe systemic inflammation and vascular remodeling.…”

Section: Ih In Ipf and Copd Combined With Osamentioning

confidence: 99%

Obstructive Sleep Apnea and Chronic Lung Disease

Ban

Lee

2019

Chronobiol Med

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are chronic disabling lung diseases that progress slowly in the elderly and are characterized by remodeling of the lung interstitium or bronchoalveolar structure. Patients with IPF or COPD have various comorbidities such as pulmonary arterial hypertension, ischemic heart disease, sleep-disordered breathing, and even cancer. Chronic hypoxia is one of the most important mechanisms in these patients and promotes changes in the lung parenchyma and vascular structure via systemic inflammation and endothelial dysfunction. Research on sleep disturbance in IPF and COPD has been vigorously conducted, and there have been reports in recent years that have suggested that obstructive sleep apnea (OSA) is closely related to disease progression and poor clinical outcomes in these two diseases. Intermittent hypoxia (IH), a key mechanism of OSA, induces further systemic inflammation and sympathetic overactivity, which may aggravate disease progression in IPF and COPD, which characteristically predispose to chronic hypoxia. Epidemiologic and experimental evidence has shown that OSA and IH could be promising targets to prevent the progression of IPF and COPD. This review provides a possible pathological mechanism of OSA and IH and suggests their promising role as emerging targets for disease control in IPF and COPD.

show abstract

“…Although it has already been used as a diagnostic marker in Japan, clinical trials has yet to validate the clinical efficacy of KL-6 [23] and further prospective studies are warranted. Recently, both hospital admissions [24••] and co-morbid obstructive sleep apnea were associated with poor outcome in IPF patients [10]. This highlights the importance of combining clinical, physiologic, and molecular variables to optimize test characteristics, rather than looking at each value in isolation.…”

Section: Idiopathic Pulmonary Fibrosismentioning

confidence: 99%

Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?

2015

View full text Add to dashboard Cite

Interstitial lung disease (ILD) covers a large spectrum of lung disorders that affects the parenchyma and is often associated with inflammation and/or fibrosis. Clinically, there is a great need for biomarker development for these disorders, to help diagnosis, treatment selection and assessment of efficacy as well as to predict progression. Thus far, no broadly validated biomarker exists for ILD, due to the existence of a very large number of disorders of often-unknown etiology, overlapping symptoms and disorders associated with a spectrum of multi-morbidities involving similar chronic inflammatory and fibrotic biochemical processes. We discuss here the development of biomarkers in IPF, sarcoidosis, connective tissue disease-associated ILD (CTD-ILD), and chronic hypersensitivity pneumonitis. We further discuss the need and opportunity to develop a multimarker approach that would be clinically meaningful for patients with ILD. Such composite index could include clinical symptoms, pathological assessment, and lung physiology measurements added to molecular information derived from bronchoalveolar lavage and serum. We also discuss the increased opportunity for patients to be involved in research as recent technological advances now allow the serial measurement of lung function using handheld spirometers, combined with handheld devices allowing measurement of patient reported outcomes, mobility, exercise, and sleep.

show abstract

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night

Cited by 58 publications

References 125 publications

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue

Obstructive Sleep Apnea and Chronic Lung Disease

Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?

Contact Info

Product

Resources

About